A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
← catalyst calendarNCT07338968 · readout in 2,552 d
Sponsored by Aura Biosciences (industry) · AURA — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
100estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-27 | actual | When the study began enrolling |
| Primary completion | 2033-08-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-08-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Choroidal Melanoma
- Indeterminate Lesions
Intervention
- Other: Observational
Primary outcome
what the primary-completion date above is the date OFIncidence of adverse events (AEs)/serious AEs.
measured 5 years
Permalink · AURA's whole pipeline · Catalyst calendar · Every registered study · What changed